Clinical Trial

A 2-part Phase 1/2 Open-label Trial on ODM-212

Name: A 2-part Phase 1/2 Open-label Trial on ODM-212 — clinical trial record (NCT07563738)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TEADCO

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

Trial Details

NCT Number	NCT07563738
Lead Sponsor	Orion Corporation, Orion Pharma
Conditions	Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment	229 participants
Start Date	2026-03-27
Primary Completion	2029-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-04